Tagomics Partners with Agilent Technologies to Revolutionize Multiomic Biomarker Discovery

Bio-Techne Partners with Leader Life Sciences to Expand in the GCC Region

Owkin and Proscia Partner to Revolutionize MSI Testing for Colorectal Cancer with AI-Powered Solutions

Telix Expands Theranostic Pipeline with FAP-Targeting Radiopharmaceuticals

Alamar Biosciences and The Michael J. Fox Foundation Partner to Advance Parkinson’s Disease Biomarker Discovery

Stilla Technologies Partners with Source BioScience to Advance Genomics in the UK and Ireland

Quell Therapeutics and AstraZeneca Advance CAR-Treg Therapy for Type 1 Diabetes

AbbVie’s ELAHERE® Approved in the EU for Platinum-Resistant Ovarian Cancer

AstraZeneca’s Tagrisso Recommended for Approval in EU for Unresectable EGFR-Mutated NSCLC

Foundation Medicine Receives FDA Approval for FoundationOne®Liquid CDx as a Companion Diagnostic for TEPMETKO® in NSCLC

Exact Sciences Partners with Carlos Ponce to Boost Colorectal Cancer Awareness in the Hispanic Community

Merck Receives Positive CHMP Opinion for KEYTRUDA® in Combination Therapy for First-Line Treatment of Non-Epithelioid Mesothelioma

Australia Launches Genomics Australia to Lead Advances in Genomic Medicine

Sidra Medicine Unveils Masterclasses Ahead of PMFG 2024 Summit

FDA Approves Revuforj® as First Menin Inhibitor for Acute Leukemia with KMT2A Translocation

Home
/
insight
/
details

The Promise and Challenges of Microbiome Therapeutics

NextEdge Admin

20 Aug 2024

3 min 19 sec

Personalized Medicine,fecal microbiota transplantation

The human microbiome includes all microorganisms and their metabolites found in and on the human body. Recent technological advancements have shed light on the gut microbiome's significant role in health and disease, positioning it as a promising target for therapeutic interventions.

Microbiome Therapy and Personalized Medicine

Microbiome therapy offers the potential for personalized treatment by addressing interpersonal variability and maintaining stability across various environments. Engineering the gut microbiome has led to the creation of chemical entities that advance personalized medicine and improve healthcare outcomes.

Strategies for Managing Dysbiosis

Dysbiosis refers to an imbalance or disruption in the composition of the microbiome, particularly the gut microbiome. This imbalance can result from various factors such as antibiotic use, poor diet, or disease, leading to a reduction in beneficial microbes and an increase in harmful ones. Dysbiosis is associated with a variety of health problems, including gastrointestinal disorders, inflammatory diseases, and even mental health issues. Restoring balance to the microbiome is a key goal in many therapeutic strategies aimed at managing dysbiosis-related conditions.

To manage dysbiosis-related disorders, strategies like fecal microbiota transplantation (FMT) and probiotics have been developed. FMT involves transferring healthy microbes from donors to recipients and has been successful in treating recurrent Clostridioides difficile infections, among other conditions. Probiotics, defined as live microorganisms that provide health benefits, are also effective in treating diseases such as inflammatory bowel disease and Crohn's disease. Engineered probiotics are being developed for more targeted disease diagnosis and treatment.

Subtractive Therapy: Targeting Pathogens

Subtractive therapy, which uses bacteriocins and bacteriophages to target harmful pathogens, offers an alternative to antibiotics, particularly in the context of rising antibiotic resistance. Bacteriocins, antimicrobial peptides produced by bacteria are used in therapeutic applications, such as treating peptic ulcers and maintaining oral health.

Challenges in Microbiome Therapeutics

Despite these advancements, the field of microbiome therapeutics faces challenges, including the identification of disease-causing microbial signatures and the need for more extensive clinical trials. Addressing these issues will be essential for realizing the full potential of microbiome-based treatments.